Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma

Molecular Biology of the Cell

Volumn 25, Issue 18, 2014, Pages 2695-2709

  Chaturvedi, Aashi ^a,b   Hoffman, Laura M ^a   Jensen, Christopher C ^a   Lin, Yi Chun ^a,b   Grossmann, Allie H ^b   Randall, R Lor ^a,b   Lessnick, Stephen L ^a,b   Welm, Alana L ^a,b   Beckerle, Mary C ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; INTEGRIN; REGULATOR PROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FLI 1; ZYXIN; CD51 ANTIGEN; EWS-FLI FUSION PROTEIN; ONCOPROTEIN; ZYX PROTEIN, HUMAN;

ACTIN FILAMENT; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL FUNCTION; CELL GROWTH; CELL SPREADING; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOSKELETON; EWING SARCOMA; EWING SARCOMA CELL LINE; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR GROWTH; ANIMAL; BONE TUMOR; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; LUNG; LUNG TUMOR; MALE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SECONDARY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CYTOSKELETON; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAV; LUNG; LUNG NEOPLASMS; MALE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; ZYXIN;

EID: 84907222566     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E14-01-0007     Document Type: Article

References (77)

1. Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, et al. (2014). Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol Oncol 8, 323-336.
2. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M (1991). MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67, 1886-1893.
3. Amsellem V, Kryszke MH, Hervy M, Subra F, Athman R, Leh H, Brachet-Ducos C, Auclair C (2005). The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells. Exp Cell Res 304, 443-456.
4. Arjonen A, Kaukonen R, Ivaska J (2011). Filopodia and adhesion in cancer cell motility. Cell Adh Migr 5, 421-430.
5. Arndt CA, Crist WM (1999). Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341, 342-352.
6. Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, Ban J, Muehlbacher K, Kreppel M, Walker RL, Meltzer P, et al. (2010). Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res 70, 4015-4023.
7. Aurias A, Rimbaut C, Buffe D, Zucker JM, Mazabraud A (1984). Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. Cancer Genet Cytogenet 12, 21-25.
8. Bernards R, Weinberg RA (2002). A progression puzzle. Nature 418, 823.
9. Borinstein SC, Barkauskas DA, Krailo M, Scher D, Scher L, Schlottmann S, Kallakury B, Dickman PS, Pawel BR, West DC, et al. (2011). Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group. Cancer 117, 4966-4976.
10. Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL (2006). Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle 5, 2753-2759.
11. Campbell ID, Humphries MJ (2011). Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol 3, a004994.
12. Cavazzana AO, Miser JS, Jefferson J, Triche TJ (1987). Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol 127, 507-518.
13. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, Cenacchi G, Preda P, Lattanzi G, Nagy B, et al. (2004). Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 23, 5664-5674.
14. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC (2012). The EWS/FLI Oncogene drives changes in cellular morphology, adhesion, and migration in Ewing sarcoma. Genes Cancer 3, 102-116.
15. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, et al. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162-165.
16. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, et al. (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17, 1514-1520.
17. Ewing J (1921). Diffuse endothelioma of bone. Proc NY Pathol Soc 21, 17-24.
18. Fellinger EJ, Garin-Chesa P, Triche TJ, Huvos AG, Rettig WJ (1991). Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 139, 317-325.
19. Geiger B, Yamada KM (2011). Molecular architecture and function of matrix adhesions. Cold Spring Harb Perspect Biol 3, a005033.
20. Guadamillas MC, Cerezo A, Del Pozo MA (2011). Overcoming anoikis-pathways to anchorage-independent growth in cancer. J Cell Sci 124, 3189-3197.
21. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES (2008). Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 7, 1807-1816.
22. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES (2005). A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11, 2662-2669.
23. Gupton SL, Riquelme D, Hughes-Alford SK, Tadros J, Rudina SS, Hynes RO, Lauffenburger D, Gertler FB (2012). Mena binds alpha5 integrin directly and modulates alpha5beta1 function. J Cell Biol 198, 657-676.
24. Hauer K, Calzada-Wack J, Steiger K, Grunewald TG, Baumhoer D, Plehm S, Buch T, Prazeres da Costa O, Esposito I, Burdach S, et al. (2013). DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. Cancer Res 73, 967-977.
25. Herrero-Martin D, Osuna D, Ordonez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gurpide J, Otero-Motta AP, Caballero G, et al. (2009). Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer 101, 80-90.
26. Hervy M, Hoffman LM, Jensen CC, Smith M, Beckerle MC (2010). The LIM protein zyxin binds CARP-1 and promotes apoptosis. Genes Cancer 1, 506-515.
27. Hoffman LM, Jensen CC, Chaturvedi A, Yoshigi M, Beckerle MC (2012). Stretch-induced actin remodeling requires targeting of zyxin to stress fibers and recruitment of actin regulators. Mol Biol Cell 23, 1846-1859.
28. Hoffman LM, Jensen CC, Kloeker S, Wang CL, Yoshigi M, Beckerle MC (2006). Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility, and deficits in actin remodeling. J Cell Biol 172, 771-782.
29. Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA (2010). Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 1224-1226.
30. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65, 8984-8992.
31. Hynes RO (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687.
32. Jedlicka P (2010). Ewing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol 3, 338-347.
33. Karosas AO (2010). Ewing's sarcoma. Am J Health Syst Pharm 67, 1599-1605.
34. Kerbel RS (1995). Significance of tumor-host interactions in cancer growth and metastases. Cancer Metastasis Rev 14, 259-262.
35. Kim YN, Koo KH, Sung JY, Yun UJ, Kim H (2012). Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol 2012 306879.
36. Kimber C, Michalski A, Spitz L, Pierro A (1998). Primitive neuroectodermal tumours: anatomic location, extent of surgery, and outcome. J Pediatr Surg 33, 39-41.
37. Kinsey M, Smith R, Lessnick SL (2006). NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 4, 851-859.
38. Kovar H (2005). Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 15, 189-196.
39. Lessnick SL, Braun BS, Denny CT, May WA (1995). Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 10, 423-431.
40. Lessnick SL, Dacwag CS, Golub TR (2002). The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1, 393-401.
41. Lotz MM, Rabinovitz I, Mercurio AM (2000). Intestinal restitution: progression of actin cytoskeleton rearrangements and integrin function in a model of epithelial wound healing. Am J Pathol 156, 985-996.
42. Lum DH, Matsen C, Welm AL, Welm BE (2012). Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Curr Protoc Pharmacol 14, 14-22.
43. Margadant F, Chew LL, Hu X, Yu H, Bate N, Zhang X, Sheetz M (2011). Mechanotransduction in vivo by repeated talin stretch-relaxation events depends upon vinculin. PLoS Biol 9, e1001223.
44. Mateo-Lozano S, Tirado OM, Notario V (2003). Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 22, 9282-9287.
45. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G, Denny CT (1993a). Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 90, 5752-5756.
46. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, Denny CT (1993b). The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13, 7393-7398.
47. McAllister NR, Lessnick SL (2005). The potential for molecular therapeutic targets in Ewing's sarcoma. Curr Treat Options Oncol 6, 461-471.
48. Mierke CT, Frey B, Fellner M, Herrmann M, Fabry B (2011). Integrin alpha5beta1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci 124, 369-383.
49. Mostafavi-Pour Z, Askari JA, Parkinson SJ, Parker PJ, Ng TT, Humphries MJ (2003). Integrin-specific signaling pathways controlling focal adhesion formation and cell migration. J Cell Biol 161, 155-167.
50. Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584-593.
51. Nagae M, Re S, Mihara E, Nogi T, Sugita Y, Takagi J (2012). Crystal structure of alpha5beta1 integrin ectodomain: atomic details of the fibronectin receptor. J Cell Biol 197, 131-140.
52. Owen LA, Kowalewski AA, Lessnick SL (2008). EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 3, e1965.
53. Owen LA, Lessnick SL (2006). Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle 5, 2049-2053.
54. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massague J (2008). TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77.
55. Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS (2011). Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol 7, 1285-1297.
56. Perlman EJ, Dickman PS, Askin FB, Grier HE, Miser JS, Link MP (1994). Ewing's sarcoma-routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Hum Pathol 25, 304-307.
57. Rajeswari J, Pande G (2006). Direct association between caspase 3 and alpha5beta1 integrin and its role during anoikis of rat fibroblasts. Cell Biol Int 30, 963-969.
58. Rodan SB, Rodan GA (1997). Integrin function in osteoclasts. J Endocrinol 154 (Suppl), S47-S56.
59. Salsmann A, Schaffner-Reckinger E, Kieffer N (2006). RGD, the Rho'd to cell spreading. Eur J Cell Biol 85, 249-254.
60. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL (2013a). Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene 32, 5089-5100.
61. Sankar S, Lessnick SL (2011). Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 204, 351-365.
62. Sankar S, Tanner JM, Bell R, Chaturvedi A, Randall RL, Beckerle MC, Lessnick SL (2013b). A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma. Mol Cell Biol 33, 4448-60.
63. Scotlandi K, Benini S, Manara MC, Serra M, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Chano T, Picci P, et al. (2000). Murine model for skeletal metastases of Ewing's sarcoma. J Orthop Res 18, 959-966.
64. Smilenov LB, Mikhailov A, Pelham RJ, Marcantonio EE, Gundersen GG (1999). Focal adhesion motility revealed in stationary fibroblasts. Science 286, 1172-1174.
65. Smith MA, Blankman E, Gardel ML, Luettjohann L, Waterman CM, Beckerle MC (2010). A zyxin-mediated mechanism for actin stress fiber maintenance and repair. Dev Cell 19, 365-376.
66. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL (2006). Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9, 405-416.
67. Spraker HL, Price SL, Chaturvedi A, Schiffman JD, Jones KB, Lessnick SL, Beckerle M, Randall RL (2012). The clone wars-revenge of the metastatic rogue state: the sarcoma paradigm. Front Oncol 2, 2.
68. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA (2001). Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155, 459-470.
69. Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H, Notario V (2006). Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 66, 9937-9947.
70. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O (2007). Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11, 421-429.
71. Truong H, Danen EH (2009). Integrin switching modulates adhesion dynamics and cell migration. Cell Adh Migr 3, 179-181.
72. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, Olschwang S, Philip I, Berger MP, et al. (1988). Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32, 229-238.
73. Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, Sharma A, Blair H, Hide IG, Heidenreich O, et al. (2014). Development of a preclinical orthotopic xenograft model of Ewing sarcoma and other human malignant bone disease using advanced in vivo imaging. PLoS One 7, e85128.
74. Wang YX, Mandal D, Wang S, Hughes D, Pollock RE, Lev D, Kleinerman E, Hayes-Jordan A (2009). Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo 23, 903-909.
75. Wiles ET, Bell R, Thomas D, Beckerle MC, Lessnick SL (2013). ZEB2 represses the epithelial phenotype and facilitates metastasis in Ewing sarcoma. Genes Cancer 4, 486-500.
76. Yoshigi M, Hoffman LM, Jensen CC, Yost HJ, Beckerle MC (2005). Mechanical force mobilizes zyxin from focal adhesions to actin filaments and regulates cytoskeletal reinforcement. J Cell Biol 171, 209-215.
77. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B (2007). Functional atlas of the integrin adhesome. Nat Cell Biol 9, 858-867.